Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,881 Shares of Company Stock

Key Points

• CEO Daniel O’Day sold 15,881 Gilead shares at an average price of $175.25, generating approximately $2.78 million. The Rule 10b5-1 transaction reduced his ownership by 2.73%, leaving him with 566,683 shares.
• Gilead’s latest quarterly results exceeded expectations, with adjusted earnings of $2.55 per share and revenue of $8.30 billion, up 6.8% year over year.
• The company declared a quarterly dividend of $0.82 per share, or $3.28 annualized, representing a 1.9% yield. Analysts maintain a generally positive view, with the stock carrying a “Moderate Buy” consensus rating.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 15,881 shares of the business's stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $175.25, for a total transaction of $2,783,145.25. Following the completion of the sale, the chief executive officer owned 566,683 shares in the company, valued at approximately $99,311,195.75. This trade represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O'day also recently made the following trade(s):

• On Monday, November 2nd, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $169.74, for a total transaction of $2,546,100.00.
• On Thursday, October 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Trading Down 0.2%

GILD stock traded down $0.35 during midday trading on Monday, reaching $170.33. 8,856,542 shares of the company traded hands, compared to its average volume of 5,751,038. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $175.65. The business has a 50 day moving average of $151.36 and a 200-day moving average of $140.03. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the previous year, the company posted $2.47 EPS. The company's revenue for the quarter was up 6.8% compared to the same quarter last year. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences's dividend payout ratio is presently -103.80%.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Alta Advisers Ltd raised its holdings in Gilead Sciences by 80.2% in the third quarter. Alta Advisers Ltd now owns 8,997 shares of the biopharmaceutical company's stock worth $1,341,000 after purchasing an additional 4,005 shares in the last quarter. Syverson Strege & Co boosted its holdings in shares of Gilead Sciences by 6.9% in the 3rd quarter. Syverson Strege & Co now owns 3,570 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 229 shares in the last quarter. Principle Wealth Partners LLC grew its position in shares of Gilead Sciences by 15.7% in the 3rd quarter. Principle Wealth Partners LLC now owns 2,788 shares of the biopharmaceutical company's stock worth $416,000 after buying an additional 378 shares during the last quarter. REAP Financial Group LLC raised its stake in shares of Gilead Sciences by 11.4% during the 3rd quarter. REAP Financial Group LLC now owns 1,380 shares of the biopharmaceutical company's stock worth $206,000 after acquiring an additional 141 shares in the last quarter. Finally, Telos Capital Management Inc. bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $215,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $175.00 target price on shares of Gilead Sciences in a research note on Monday. Wells Fargo & Company increased their price target on Gilead Sciences from $165.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday. Zacks Research lowered Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 29th. Finally, Leerink Partners downgraded Gilead Sciences from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $169.74.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.